For Research Use Only. Not for Clinical Use.

A variety of methods have been used for half-life extension. Creative Biolabs is proficient in various ways for extending the half-life of different drugs. We are proud to offer our clients the most suitable way of half-life extending according to the characteristics of the target drugs.

Fig.1 T-cell Lymphoma.

Introduction of T-cell Lymphoma

T-cell lymphoma is a malignant tumor with abnormal proliferation of T cells. It belongs to a special type of T-cell non-Hodgkin lymphomas with a low incidence, but a high degree of malignancy. The clinical manifestations of the disease include swollen lymph nodes, scattered erythema on the skin, hypercalcemia, and bone erosion disorders. Patient with T-cell lymphoma is more prone to infection than ordinary people. Once the disease is diagnosed, the patient's prognosis is poor, associated with poor one-year survival. In addition, compared with females, T-cell lymphoma has a greater incidence in males.

Application of Half-life Extended Drug in T-cell Lymphoma

• Recently, a great increase incidence of T-cell lymphoma has been confirmed. Although several new agents have been approved for T-cell lymphoma, the outcomes are not obvious. Romidepsin is a novel, well-tolerated histone deacetylase inhibitor with promising activity against advanced stages of lymphoma. It was approved by the US Food and Drug Administration for treating T-cell lymphoma. The drug is a valuable, new agent that has shown remarkable activity, good durability, and tolerable side effects in the treatment of T-cell lymphomas. Besides, some research indicated that the prodrug form of romidepsin has a longer half-life and romidepsin is quite stable in the prodrug form. Romidepsin belongs to the histone deacetylase inhibitors (HDACis) that are known to have an impact on the gene and protein function by epigenetic modulation. Vorinostat is another HDACi approved for lymphoma. HDACis showed significant activity signals in several T-cell malignancies, including T-cell lymphoma.
• As shown by the data, a number of therapeutic monoclonal antibodies (mAbs) applicable to tumors have been approved. In the past 20 years, the nature of the mAbs has changed drastically. Moreover, the recently registered mAbs are mostly IgG1, IgG2, IgG3 or IgG4 humanized or 100% human. Compared with the previous mAbs, newly developed mAbs have more advantages, such as a higher systemic clearance and a longer half-life. Doses and administration frequency are based on nature. Experiments show that new mAbs may play an important role in lymphoma.

The choice of an appropriate method is critical to the project. As a leader in this field, Creative Biolabs will provide customers with the best way to extend the half-life of the target drug. Please feel free to contact us for more information.